Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday a late-breaking poster on its Phase 2a study of intranasal foralumab ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that a ...
Cartesian Therapeutics, Inc. (RNAC) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 9:30 AM EDTCompany ParticipantsCarsten Brunn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results